无进展生存期-话题@MedSci

#无进展生存期#

56篇内容 | 2903人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1459677, encodeId=1f9f14596e76e, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=阿斯利康携手第一三共开发的trastuzumab deruxtecan研究结果喜人，HER2阳性转移性乳腺癌患者中位无进展生存期达16.4个月 , objectType=article, longId=184672, objectId=90f01846e265, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=90f01846e265, replyNumber=0, likeNumber=64, createdTime=2019-12-14, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=90f01846e265, moduleTitle=阿斯利康携手第一三共开发的trastuzumab deruxtecan研究结果喜人，HER2阳性转移性乳腺癌患者中位无进展生存期达16.4个月 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=90f01846e265)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459676, encodeId=844a14596e6b5, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=2019 ESMO：PARP抑制剂Niraparib可显着提高化疗成功的晚期卵巢癌患者无进展生存期, objectType=article, longId=180550, objectId=a9941805506a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9941805506a, replyNumber=0, likeNumber=79, createdTime=2019-10-07, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9941805506a, moduleTitle=2019 ESMO：PARP抑制剂Niraparib可显着提高化疗成功的晚期卵巢癌患者无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a9941805506a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459675, encodeId=4aca14596e5d4, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=BMS的PD-1单抗Opdivo：未能在III期临床改善多形性胶质母细胞瘤患者的无进展生存期, objectType=article, longId=178992, objectId=cb1b1e899242, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb1b1e899242, replyNumber=0, likeNumber=71, createdTime=2019-09-07, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb1b1e899242, moduleTitle=BMS的PD-1单抗Opdivo：未能在III期临床改善多形性胶质母细胞瘤患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb1b1e899242)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459674, encodeId=0f4314596e4dd, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=JCO：生长抑素类似物治疗晚期神经内分泌肿瘤患者的无进展生存期的预测：GETNE-TRASGU研究, objectType=article, longId=177361, objectId=414c1e7361c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=414c1e7361c0, replyNumber=0, likeNumber=82, createdTime=2019-08-11, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=414c1e7361c0, moduleTitle=JCO：生长抑素类似物治疗晚期神经内分泌肿瘤患者的无进展生存期的预测：GETNE-TRASGU研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=414c1e7361c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459673, encodeId=864514596e3f3, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=Zejula显著延长卵巢癌患者的无进展生存期, objectType=article, longId=175550, objectId=7f621e55508b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f621e55508b, replyNumber=0, likeNumber=91, createdTime=2019-07-17, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f621e55508b, moduleTitle=Zejula显著延长卵巢癌患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f621e55508b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459672, encodeId=8f8a14596e213, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=2019 ESMO胃肠癌世界大会：奥拉帕尼维持治疗改善了BRCA突变的转移性胰腺癌患者的无进展生存期, objectType=article, longId=175101, objectId=26291e5101bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26291e5101bd, replyNumber=0, likeNumber=73, createdTime=2019-07-11, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26291e5101bd, moduleTitle=2019 ESMO胃肠癌世界大会：奥拉帕尼维持治疗改善了BRCA突变的转移性胰腺癌患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26291e5101bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459671, encodeId=047314596e125, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=2019 EHA：AZ的BTK抑制剂Calquence显着延长慢性淋巴细胞白血病患者的无进展生存期, objectType=article, longId=168695, objectId=da9416869531, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=da9416869531, replyNumber=0, likeNumber=63, createdTime=2019-06-20, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=da9416869531, moduleTitle=2019 EHA：AZ的BTK抑制剂Calquence显着延长慢性淋巴细胞白血病患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=da9416869531)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459670, encodeId=4e0b14596e058, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=JAMA Intern Med：癌症临床试验：无进展生存期更长表明患者生活质量更佳？, objectType=article, longId=157462, objectId=fd3615e46273, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd3615e46273, replyNumber=0, likeNumber=107, createdTime=2019-01-08, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd3615e46273, moduleTitle=JAMA Intern Med：癌症临床试验：无进展生存期更长表明患者生活质量更佳？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd3615e46273)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459669, encodeId=4f33145966919, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=索拉非尼可改善纤维瘤患者的无进展生存期, objectType=article, longId=134228, objectId=4eac1342289c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4eac1342289c, replyNumber=0, likeNumber=84, createdTime=2018-04-05, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4eac1342289c, moduleTitle=索拉非尼可改善纤维瘤患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4eac1342289c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459668, encodeId=838e145966898, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=【2017 ASH】RESONATE-2研究证实对于未经治疗的慢性淋巴细胞白血病患者，伊布替尼单药在延长无进展生存期和安全性方面均优于多种免疫化疗方案, objectType=article, longId=123151, objectId=925712315133, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=925712315133, replyNumber=0, likeNumber=75, createdTime=2017-12-14, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=925712315133, moduleTitle=【2017 ASH】RESONATE-2研究证实对于未经治疗的慢性淋巴细胞白血病患者，伊布替尼单药在延长无进展生存期和安全性方面均优于多种免疫化疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=925712315133)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459667, encodeId=9c86145966e2f, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=诺华kisqali表明可显著延长绝经前乳腺癌患者的无进展生存期, objectType=article, longId=122722, objectId=f09b122e2259, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f09b122e2259, replyNumber=0, likeNumber=110, createdTime=2017-12-09, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f09b122e2259, moduleTitle=诺华kisqali表明可显著延长绝经前乳腺癌患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f09b122e2259)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459666, encodeId=c655145966603, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=Lancet Oncol：来曲唑治疗方案对早期乳腺癌患者无进展生存期的影响, objectType=article, longId=120823, objectId=c0e612082300, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c0e612082300, replyNumber=0, likeNumber=82, createdTime=2017-11-22, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c0e612082300, moduleTitle=Lancet Oncol：来曲唑治疗方案对早期乳腺癌患者无进展生存期的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c0e612082300)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459665, encodeId=d1fa145966524, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=肿瘤治疗电场为复发性卵巢癌患者带来新希望，无进展生存期延长两倍！, objectType=article, longId=117443, objectId=670111e4433a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=670111e4433a, replyNumber=0, likeNumber=122, createdTime=2017-10-26, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=670111e4433a, moduleTitle=肿瘤治疗电场为复发性卵巢癌患者带来新希望，无进展生存期延长两倍！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=670111e4433a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459664, encodeId=580014596644c, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=Blood：Ixazomib显着延长复发性/难治性骨髓瘤患者的无进展生存期。, objectType=article, longId=117234, objectId=e31c11e2342c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e31c11e2342c, replyNumber=0, likeNumber=66, createdTime=2017-10-25, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e31c11e2342c, moduleTitle=Blood：Ixazomib显着延长复发性/难治性骨髓瘤患者的无进展生存期。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e31c11e2342c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459663, encodeId=c2a81459663f5, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=Ann Oncol：使用β－肾上腺素受体阻断剂能显著改善的HER2阴性的晚期乳腺癌患者的无进展生存期, objectType=article, longId=111335, objectId=5da0111335c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5da0111335c2, replyNumber=0, likeNumber=70, createdTime=2017-08-31, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5da0111335c2, moduleTitle=Ann Oncol：使用β－肾上腺素受体阻断剂能显著改善的HER2阴性的晚期乳腺癌患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5da0111335c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459662, encodeId=7ce01459662bd, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=Clin Cancer Res：基于多参数磁共振影像组学预测晚期鼻咽癌患者无进展生存期, objectType=article, longId=111122, objectId=012d111122af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=012d111122af, replyNumber=0, likeNumber=90, createdTime=2017-08-30, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=012d111122af, moduleTitle=Clin Cancer Res：基于多参数磁共振影像组学预测晚期鼻咽癌患者无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=012d111122af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459661, encodeId=528f14596615c, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=ASCO:肺癌患者无进展生存期新药显著延长脑转移患者无进展生存期, objectType=article, longId=100969, objectId=8290100969be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8290100969be, replyNumber=0, likeNumber=83, createdTime=2017-06-08, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8290100969be, moduleTitle=ASCO:肺癌患者无进展生存期新药显著延长脑转移患者无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8290100969be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459660, encodeId=f06a1459660bd, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=NEJM：Palbociclib+来曲唑治疗可显著延长晚期乳腺癌患者的无进展生存期, objectType=article, longId=82539, objectId=ade982539bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ade982539bd, replyNumber=0, likeNumber=125, createdTime=2016-11-18, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ade982539bd, moduleTitle=NEJM：Palbociclib+来曲唑治疗可显著延长晚期乳腺癌患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ade982539bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459659, encodeId=cee2145965963, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=ESMO 2016：氟维司群可延长乳腺癌患者的无进展生存期（FALCON试验）, objectType=article, longId=79621, objectId=d717e96216e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d717e96216e, replyNumber=0, likeNumber=78, createdTime=2016-10-11, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d717e96216e, moduleTitle=ESMO 2016：氟维司群可延长乳腺癌患者的无进展生存期（FALCON试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d717e96216e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1459658, encodeId=029d14596588a, content=<a href='/topic/show?id=565f5916816' target=_blank style='color:#2F92EE;'>#无进展生存期#</a>, objectTitle=NEJM：Niraparib可显著延长铂敏感的复发性卵巢癌患者无进展生存期, objectType=article, longId=79605, objectId=925ae9605d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=925ae9605d0, replyNumber=0, likeNumber=117, createdTime=2016-10-10, rootId=0, userName=zhangfenasdf, userId=0c466182591, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=925ae9605d0, moduleTitle=NEJM：Niraparib可显著延长铂敏感的复发性卵巢癌患者无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=925ae9605d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

无进展生存期

2020-05-29

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

阿斯利康携手第一三共开发的trastuzumab deruxtecan研究结果喜人，HER2阳性转移性乳腺癌患者中位无进展生存期达16.4个月 

2019-12-14

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

2019 ESMO：PARP抑制剂Niraparib可显着提高化疗成功的晚期卵巢癌患者无进展生存期

2019-10-07

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

BMS的PD-1单抗Opdivo：未能在III期临床改善多形性胶质母细胞瘤患者的无进展生存期

2019-09-07

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

JCO：生长抑素类似物治疗晚期神经内分泌肿瘤患者的无进展生存期的预测：GETNE-TRASGU研究

2019-08-11

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

Zejula显著延长卵巢癌患者的无进展生存期

2019-07-17

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

2019 ESMO胃肠癌世界大会：奥拉帕尼维持治疗改善了BRCA突变的转移性胰腺癌患者的无进展生存期

2019-07-11

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

2019 EHA：AZ的BTK抑制剂Calquence显着延长慢性淋巴细胞白血病患者的无进展生存期

2019-06-20

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

JAMA Intern Med：癌症临床试验：无进展生存期更长表明患者生活质量更佳？

2019-01-08

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

索拉非尼可改善纤维瘤患者的无进展生存期

2018-04-05

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

【2017 ASH】RESONATE-2研究证实对于未经治疗的慢性淋巴细胞白血病患者，伊布替尼单药在延长无进展生存期和安全性方面均优于多种免疫化疗方案

2017-12-14

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

诺华kisqali表明可显著延长绝经前乳腺癌患者的无进展生存期

2017-12-09

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

Lancet Oncol：来曲唑治疗方案对早期乳腺癌患者无进展生存期的影响

2017-11-22

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

肿瘤治疗电场为复发性卵巢癌患者带来新希望，无进展生存期延长两倍！

2017-10-26

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

Blood：Ixazomib显着延长复发性/难治性骨髓瘤患者的无进展生存期。

2017-10-25

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

Ann Oncol：使用β－肾上腺素受体阻断剂能显著改善的HER2阴性的晚期乳腺癌患者的无进展生存期

2017-08-31

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

Clin Cancer Res：基于多参数磁共振影像组学预测晚期鼻咽癌患者无进展生存期

2017-08-30

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

ASCO:肺癌患者无进展生存期新药显著延长脑转移患者无进展生存期

2017-06-08

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

NEJM：Palbociclib+来曲唑治疗可显著延长晚期乳腺癌患者的无进展生存期

2016-11-18

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

ESMO 2016：氟维司群可延长乳腺癌患者的无进展生存期（FALCON试验）

2016-10-11

zhangfenasdf (审核中...)

前往app查看评论内容

#无进展生存期#

NEJM：Niraparib可显著延长铂敏感的复发性卵巢癌患者无进展生存期

2016-10-10

科室
- - 订阅+
  - 更多科室
工具
服务